|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-4.03/-0.25
|
企业价值
439.13M
|
资产负债 |
每股账面净值
0.41
|
现金流量 |
现金流量率
--
|
损益表 |
收益
687.20M
|
每股收益
0.48
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/05 11:48 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
YS Biopharma Co Ltd is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. It developed a PIKA immunomodulating technology platform and a series of product candidates targeting rabies, hepatitis B, influenza and other indications. It is also conducting the production and sale of YSJA, a rabies vaccine, the first aluminium-free lyophilized rabies vaccine that was launched in China. It has one operating segment, whichis the development, production, marketing and sale of biopharmaceutical products. |